rs730880130
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PM1PM2PM5PP3_StrongPP5_Very_Strong
The NM_000527.5(LDLR):c.1468T>C(p.Trp490Arg) variant causes a missense change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. W490G) has been classified as Likely pathogenic.
Frequency
Consequence
NM_000527.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
LDLR | NM_000527.5 | c.1468T>C | p.Trp490Arg | missense_variant | Exon 10 of 18 | ENST00000558518.6 | NP_000518.1 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 35
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Hypercholesterolemia, familial, 1 Pathogenic:5
- -
subject mutated among 2600 FH index cases screened = 1 / previously described in association with FH/Software predictions: Conflicting -
- -
0/208 non-FH alleles -
- -
Familial hypercholesterolemia Pathogenic:2
Variant summary: LDLR c.1468T>C (p.Trp490Arg) results in a non-conservative amino acid change located in the LDL-receptor class B3 domain (LOVD database) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 251404 control chromosomes. c.1468T>C has been reported in the literature in individuals affected with Familial Hypercholesterolemia (example, Bourbon_2008, Silva_2012, Bertolini_2013, Futema_2021). These data indicate that the variant is likely to be associated with disease. At least two publications report experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in only 5% of normal LDLR activity and that this mutant protein is mainly retained in the ER (example, Silva_2012, Etxebarria_2014). Five clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic (n=1)/likely pathogenic (n=4). Based on the evidence outlined above, the variant was classified as pathogenic. -
This variant is not present in population databases (gnomAD no frequency). For these reasons, this variant has been classified as Pathogenic. Experimental studies have shown that this missense change affects LDLR function (PMID: 23021490, 25386756). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). ClinVar contains an entry for this variant (Variation ID: 180402). This variant is also known as W469R. This missense change has been observed in individuals with familial hypercholesterolemia (PMID: 17765246, 23021490, 23375686, 31345425; Invitae). This sequence change replaces tryptophan, which is neutral and slightly polar, with arginine, which is basic and polar, at codon 490 of the LDLR protein (p.Trp490Arg). -
Cardiovascular phenotype Pathogenic:1
The p.W490R pathogenic mutation (also known as c.1468T>C), located in coding exon 10 of the LDLR gene, results from a T to C substitution at nucleotide position 1468. The tryptophan at codon 490 is replaced by arginine, an amino acid with dissimilar properties. This variant (also referred to as p.W469R) has been detected in unrelated individuals reported to have familial hypercholesterolemia (FH), and was reported to segregate with disease in families (Bourbon M et al. Atherosclerosis, 2008 Feb;196:633-42; Silva S et al. Atherosclerosis, 2012 Nov;225:128-34; Bertolini S et al. Atherosclerosis, 2013 Apr;227:342-8; Trinder M et al. J Am Coll Cardiol, 2019 07;74:512-522; Futema M et al. Atherosclerosis, 2021 02;319:108-117). This variant has also been detected in trans with a second mutation in the LDLR gene in an individual reported to have homozygous FH (Gao M et al. Front Pediatr, 2020 Oct;8:535949). In in vitro functional studies, this variant resulted in impaired protein expression and activity (Silva S et al. Atherosclerosis, 2012 Nov;225:128-34; Etxebarria A et al. PLoS One, 2014 Nov;9:e112677). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at